We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+7.35%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$438M
AUM Growth
+$79M
Cap. Flow
+$165M
Cap. Flow %
37.75%
Top 10 Hldgs %
55.67%
Holding
153
New
56
Increased
27
Reduced
23
Closed
42

Top Buys

Rank Stock Value
1
SMMF
Summit Financial Group, Inc.
SMMF
+$111M
2
NVS icon
Novartis
NVS
+$41.1M
3
RDHL
Redhill Biopharma
RDHL
+$23M
4
JNJ icon
Johnson & Johnson
JNJ
+$20M
5
LLY icon
Eli Lilly
LLY
+$16.7M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$9.18M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$7.75M
3
QQQ icon
Invesco QQQ Trust
QQQ
+$7.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.09M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$3.12M

Sector Composition

Rank Sector Weight
1 Healthcare 73.63%
2 Consumer Discretionary 3%
3 Technology 2.66%
4 Industrials 1.84%
5 Consumer Staples 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSX icon
26
CSX Corp
CSX
$93.4B
$3.38M 0.77%
350,475
+130,500
+59% +$1.21M
TEVA icon
27
Teva Pharmaceuticals
TEVA
$40.8B
$3.25M 0.74%
61,600
-88,400
-59% -$4.09M
GOOG icon
28
Alphabet (Google) Class C
GOOG
$4.36T
$3.19M 0.73%
+114,989
New +$3.35M
PCP
29
DELISTED
PRECISION CASTPARTS CORP
PCP
$3.17M 0.72%
12,520
+2,000
+19% +$518K
XLI icon
30
State Street Industrial Select Sector SPDR ETF
XLI
$32.8B
$2.86M 0.65%
54,623
-40,000
-42% -$2.05M
CLVS
31
DELISTED
Clovis Oncology, Inc.
CLVS
$2.77M 0.63%
40,000
-5,000
-11% -$367K
CVS icon
32
CVS Health
CVS
$133B
$2.68M 0.61%
+35,795
New +$2.53M
BKNG icon
33
Booking.com
BKNG
$149B
$2.67M 0.61%
56,050
+6,675
+14% +$329K
TEVA icon
34
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$2.53M 0.58%
3,000
-97,000
-97% -$4.48M
TBRA
35
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$2.5M 0.57%
+22,222
New +$1.56M
RDHL
36
Redhill Biopharma
RDHL
$3.95M
$2.43M 0.55%
+1,715
New +$23M
NGNE icon
37
Neurogene
NGNE
$656M
$2.42M 0.55%
+9,500
New +$2.44M
AERI
38
DELISTED
Aerie Pharmaceuticals
AERI
$2.38M 0.54%
112,500
+2,500
+2% +$50.5K
NPSP
39
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$2.33M 0.53%
78,000
-50,000
-39% -$1.72M
LVS icon
40
Las Vegas Sands
LVS
$31.7B
$2.25M 0.51%
27,847
+3,170
+13% +$255K
CASC
41
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.21M 0.5%
123,056
-1,667
-1% -$27.4K
IRD
42
Opus Genetics
IRD
$306M
$2.17M 0.49%
4,180
+1,055
+34% +$571K
PRTA icon
43
Prothena Corp
PRTA
$425M
$2.11M 0.48%
55,000
+5,000
+10% +$161K
NVMI
44
Nova
NVMI
$12.4B
$2.03M 0.46%
+181,184
New +$2M
SILC icon
45
Silicom
SILC
$229M
$1.99M 0.45%
32,088
-5,733
-15% -$354K
TRVN
46
DELISTED
Trevena, Inc.
TRVN
$1.97M 0.45%
+400
New +$1.96M
GLMD icon
47
Galmed Pharmaceuticals
GLMD
$5.13M
$1.95M 0.45%
+944
New +$2.21M
SCHW
48
Charles Schwab
SCHW
$183B
$1.89M 0.43%
69,200
-28,727
-29% -$751K
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.82M 0.42%
+100,000
New +$1.81M
CHKP icon
50
Check Point Software Technologies
CHKP
$13B
$1.79M 0.41%
26,513
-28,840
-52% -$1.91M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sphera Funds Management held 153 positions worth $438M, up 22% from $359M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sphera Funds Management deployed $165M of net new capital in Q1 2014, opening 56 new positions and adding to 27 existing holdings. Its largest new stake was Summit Financial Group, Inc.: 10,921,656 shares worth $1.75M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $4.09M trimmed.

  • Sphera Funds Management's largest Q1 2014 buy was Summit Financial Group, Inc.: 10,921,656 shares worth $1.75M.
  • Sphera Funds Management added most to Novartis in Q1 2014, an estimated $41.1M increase.
  • Sphera Funds Management's biggest Q1 2014 reduction was Teva Pharmaceuticals, cutting an estimated $4.09M.
  • Sphera Funds Management fully exited Shire pic in Q1 2014, selling an estimated $9.18M.
  • Sphera Funds Management's ten largest holdings make up 56% of its $438M portfolio in Q1 2014.
  • Sphera Funds Management opened 56 new positions and closed 42 in Q1 2014.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $438M.

Based on Sphera Funds Management's 13F filing for Q1 2014, filed 14 May 2014.